AIM ImmunoTech (AIM) Non-Current Debt (2017 - 2026)

AIM ImmunoTech's (AIM) quarterly Non-Current Debt came in at $210000.0 in Q1 2026, down 77.35% on a QoQ basis from $927000.0 in Q4 2025.

AIM ImmunoTech (AIM) Non-Current Debt (2017 - 2026) Analysis & Trends

AIM ImmunoTech (AIM) has 8 years of Non-Current Debt data on file, last reported at $210000.0 in Q1 2026.

Quarterly Non-Current Debt changed N/A year-over-year to $210000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $210000.0 (changed N/A YoY) and the FY2025 annual result came in at $927000.0, changed N/A from the prior year.
Non-Current Debt slipped to $210000.0 in Q1 2026, from $927000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $950000.0 in Q1 2024 to a low of $139000.0 in Q3 2024.
A 3-year average of $501800.0 and a median of $283000.0 in 2024 frame the typical range for Non-Current Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.81 Bn	131.96 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.56 Bn	78.56 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.72 Bn	60.53 Bn	1.37 Bn	-
4	Moderna	58.75 Bn	53.61 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	-
7	BioNTech SE	28.59 Bn	10.19 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.63 Bn	26.47 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.24 Bn	26.40 Bn	-	8.96 Bn
10	AIM ImmunoTech	4.45 Mn	-5.52 Mn	21,000.00	-

Download Data